Innovative Therapeutics IgGenix specializes in developing monoclonal IgG4 antibodies for allergic diseases, including peanut allergy and alpha-gal syndrome, positioning them as a leader in revolutionary allergy treatment solutions.
Strong Funding Support With a recent $40 million Series B financing led by Alexandria Venture Investments, IgGenix demonstrates robust investor confidence, enabling continued research, product development, and expansion in the biotech space.
Strategic Industry Presence Participation in prominent events such as the AAAAI / WAO Joint Congress indicates active engagement with key industry stakeholders and potential partners in allergy and immunology sectors.
Technological Edge Utilizing advanced proprietary technology to re-engineer human antibodies, IgGenix is well-positioned to deliver innovative therapies that can be integrated into healthcare providers' allergy treatment offerings.
Market Growth Potential The company's focus on severe allergy therapeutics, combined with its early-stage revenue and strategic scientific advances, suggests significant opportunities for partnerships with pharmaceutical companies and healthcare providers seeking novel allergy solutions.
IgGenix, Inc uses 8 technology products and services including Site Kit, RSS, MySQL, and more. Explore IgGenix, Inc's tech stack below.
| IgGenix, Inc Email Formats | Percentage |
| FLast@iggenix.com | 33% |
| FirstL@iggenix.com | 17% |
| FLast@iggenix.com | 33% |
| FirstL@iggenix.com | 17% |
Biotechnology ResearchCalifornia, United States11-50 Employees
IgGenix is a clinical-stage, venture backed biotechnology company founded on breakthrough advances in Steve Quake’s laboratory at Stanford in collaboration with allergy clinician and researcher Kari Nadeau. We have exciting opportunities for enthusiastic, self-motivated, and highly organized individuals to join the growing team at IgGenix in South San Francisco, CA.
Company Overview
Media & News
Funding & FinancialsIgGenix, Inc has raised a total of $40M of funding over 4 rounds. Their latest funding round was raised on Feb 06, 2023 in the amount of $40M.
IgGenix, Inc's revenue is estimated to be in the range of $10M$25M
Funding & FinancialsIgGenix, Inc has raised a total of $40M of funding over 4 rounds. Their latest funding round was raised on Feb 06, 2023 in the amount of $40M.
IgGenix, Inc's revenue is estimated to be in the range of $10M$25M
1-888-653-2347 
support@leadiq.com